ACADIA Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACAD Nasdaq 2836 www.acadia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Jun 24th, 2025 11:05 am
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent - Jun 20th, 2025 2:02 pm
High Growth Tech Stocks In The US Market June 2025 - Jun 18th, 2025 11:38 am
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Jun 18th, 2025 5:50 am
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 17th, 2025 2:05 pm
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Jun 11th, 2025 5:40 pm
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Jun 9th, 2025 2:01 pm
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - Jun 5th, 2025 7:05 am
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - May 29th, 2025 2:05 pm
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise - May 27th, 2025 2:05 pm
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - May 20th, 2025 10:52 am
Biotech Alert: Searches spiking for these stocks today - May 20th, 2025 8:55 am
ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 - May 19th, 2025 1:07 pm
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer - May 17th, 2025 11:36 am
Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital - May 17th, 2025 11:36 am
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation - May 16th, 2025 11:43 am
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - May 9th, 2025 4:26 pm
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - May 8th, 2025 8:40 am
ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - May 8th, 2025 1:28 am
Acadia: Q1 Earnings Snapshot - May 7th, 2025 2:30 pm